Focusing on certain EV markers and comparing their expression in different leukemic and healthy samples, we demonstrated differences: As given in Fig. 4, significantly lower frequencies of platelet-derived EV CD42a marker expression was found in AML and ALL compared to CLL samples, platelet-derived EV CD62P was found with (borderline significantly) lower frequencies in AML compared to CLL samples and significantly lower frequencies in ALL compared to CLL samples. This evidence concerns the gene GP9 and B-cell chronic lymphocytic leukemia.